Insider transactions

Patrick G Lepore

CIK 1055404 · Executive Chairman · last filed 2025-12-15

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$1.22M
Companies
6
Total Filings
79
Lifetime Open-Market Net
$966.0K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

PRX price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
17-17 ROUTE 208 N
FAIRLAWN, NJ 07410
Related Filers
Innoviva, Inc. — 3 joint filings, latest 2017-04-24
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
VYNE Therapeutics Inc. (VYNE) Delisted Director 1,029 $28.56 $29.4K $399.9K 15 2025-12-15
LANNETT CO INC (LCI) Delisted Director 146,786 $0.69 $100.6K $1.65M 16 2022-11-14
MTNB Director 533 $1.66 $885 $345.7K 8 2020-11-10
PharMerica CORP (PMC) Delisted Director 0 — — $0 7 2017-12-08
INVA Director 58,278 $20.96 $1.22M $0 2 2017-04-24
PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted Chairman and CEO 214,793 — — -$1.43M 30 2012-01-13

Recent Filings · Page 5 of 8

79 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2017-06-16 PharMerica CORP (PMC) Delisted Grant (A) +4,817 $0 EDGAR
2017-04-24 INVA Grant (A) +19,857 $0 EDGAR
2016-10-27 INVA Grant (A) +38,421 $0 EDGAR
2016-06-21 PharMerica CORP (PMC) Delisted Grant (A) +5,167 $0 EDGAR
2015-06-23 PharMerica CORP (PMC) Delisted Grant (A) +3,730 $0 EDGAR
2013-07-03 PharMerica CORP (PMC) Delisted Grant (A) +5,556 $0 EDGAR
2013-06-19 PharMerica CORP (PMC) Delisted Grant (A) +5,685 $0 EDGAR
2013-01-14 PharMerica CORP (PMC) Delisted Grant (A) +6,000 $0 EDGAR
2012-10-02 — Disp (D) −229,792 -$11.49M
2012-01-13 PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted Tax (F) −1,652 -$58.9K EDGAR
Showing 41–50 of 79
Page 5 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.